Double Bond Pharmaceutical International AB Logo

Double Bond Pharmaceutical International AB

Redevelops drugs with targeted delivery to improve safety and efficacy.

DBP B | SPGR

Overview

Corporate Details

ISIN(s):
SE0007185517 (+1 more)
LEI:
254900U1MWE2YSPREX74
Country:
Sweden
Address:
Virdings Alle 32B, 754 50 Uppsala

Description

Double Bond Pharmaceutical International AB is a pharmaceutical company that focuses on redeveloping established drugs into new formulations to improve safety and efficacy. The company's core strategy involves changing the route of administration and utilizing proprietary drug delivery technologies. Its main technology platform, BeloGal®, is a biomimetic encapsulation system designed for targeted drug delivery to specific organs, aiming to increase therapeutic effects while reducing systemic toxicity. The development pipeline is focused on treatments for high-need areas, including cancer and infectious diseases. Key candidates in the pipeline include SI-053, a locally administered temozolomide gel for glioblastoma; SA-033, a targeted doxorubicin formulation for liver cancer; and Belopenem, which directs the antibiotic meropenem to the lungs to treat pneumonia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Double Bond Pharmaceutical International AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Double Bond Pharmaceutical International AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Double Bond Pharmaceutical International AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.